June 5th 2023
By Jason Broderick
After a median follow-up of four years, the survival benefit, including progression-free survival persisted in patients with advanced clear cell renal cell carcinoma treated with Lenvima plus Keytruda compared with those treated with Sutent.
June 5th 2023
By Brielle Benyon
Longer follow-up data showed that Lenvima plus Keytruda still outperformed Sutent in the treatment of patients with advanced renal cell carcinoma.
June 5th 2023
By Kristi Rosa
Patients with locally advanced rectal cancer treated with FOLFOX before surgery had similar outcomes and side effect profiles to those treated with presurgical pelvic chemoradiation.
June 5th 2023
By Brielle Benyon
Adding Opdivo and Yervoy to Cabometyx led to improved progression-free survival and disease control rates in patients with soft tissue sarcoma, recent research showed.
June 5th 2023
By Ron Cooper
I’m mourning the death of a patient with cancer who I had never met in person, yet I loved and admired her just the same.
June 5, 2023 5:00 PM
By Ron Cooper
June 2, 2023 5:00 PM
By Debbie Legault
June 1, 2023 9:00 PM
By Linda Cohen
June 1, 2023 5:00 PM
By Elizabeth McSpadden
May 12, 2023 7:00 PM
By Bryana Tanner
May 11, 2023 9:00 PM
By Robert Trebor
May 8, 2023 9:00 PM
By Denise Sirchie
May 4, 2023 1:00 PM
By Chester Freeman